Talis Biomedical Corporation (TLIS)
OTCMKTS · Delayed Price · Currency is USD
1.600
0.00 (0.00%)
At close: Dec 3, 2025
Talis Biomedical Revenue
Talis Biomedical had revenue of $408.00K in the twelve months ending June 30, 2024, down -85.69% year-over-year. In the year 2023, Talis Biomedical had annual revenue of $2.13M, down -55.65%.
Revenue (ttm)
408.00K
Revenue Growth
-85.69%
P/S Ratio
7.15
Revenue / Employee
4.12K
Employees
99
Market Cap
2.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2.13M | -2.68M | -55.65% |
| Dec 31, 2022 | 4.81M | -3.38M | -41.27% |
| Dec 31, 2021 | 8.19M | -2.75M | -25.10% |
| Dec 31, 2020 | 10.94M | 6.96M | 175.03% |
| Dec 31, 2019 | 3.98M | 1.59M | 66.40% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Silence Therapeutics | 25.83M |
| Northwest Biotherapeutics | 937.00K |
Talis Biomedical News
- 1 year ago - Baker Bros. Advisors LP's Strategic Acquisition in Talis Biomedical Corp - GuruFocus
- 2 years ago - Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash - GlobeNewsWire
- 2 years ago - Talis Biomedical Corporation (TLIS) Q2 2023 Earnings Call Transcript - Seeking Alpha
- 2 years ago - Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update - GlobeNewsWire
- 2 years ago - Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023 - GlobeNewsWire
- 2 years ago - Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO) - GlobeNewsWire
- 2 years ago - Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 2 years ago - Talis Biomedical Announces 1-for-15 Reverse Stock Split - GlobeNewsWire